Repligen (RGEN) Reports In-Line Q3 EPS

Repligen (NASDAQ: RGEN) reported Q3 EPS of $0.04, in-line with the analyst estimate of $0.04. Revenue for the quarter came in at $15.3 million versus the consensus estimate of $15.6 million.

Repligen sees FY2014 revenue of $60-62 million, versus prior guidance of $59-62 million and the consensus of $0.28 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Assurant (AIZ) is Piper Sandler's Weekly Focus Idea
• Notice to Long-Term Shareholders of Badger Meter, Inc. (NYSE: BMI); GeneDx Holdings Corp. (NASDAQ: WGS); GRAIL, Inc. (NASDAQ: GRAL); and Verra Mobility Corporation (NASDAQ: VRRM): Grabar Law Office i